LncRNA Information | |||||
---|---|---|---|---|---|
ID | EL0024 | Name | 6030408B16RIK | Aliases | N/A |
Species | Rattus norvegicus | Chromosome | N/A | Start site | N/A |
End site | N/A | Chain | N/A | Exon NO. | N/A |
Assembly | N/A | Class | lncRNA | NCBI accession | N/A |
Ensembl | N/A | Sequence | N/A | Peptide-related | N/A |
CircRNA | N/A | Exosomal | N/A | Structure | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Drug/chemo/stress | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | ||
ultrafiltration failure | qRT-PCR, western blot, luciferase, RIP | PD. Peritoneal tissues | up-regulated | interaction | In summary, lncRNA 6030408B16RIK silencing exerts anti-fibrotic effect on uremic PD rats with ultrafiltration failure by inactivating the WISP2-dependent Wnt/β-catenin pathway via miR-326-3p. | 32255479 |
Interaction | |||||||||
---|---|---|---|---|---|---|---|---|---|
Interaction target | Level of interaction | Type of interaction | Methods | Description | PMID | ||||
miR-326-3p | RNA-RNA | binding | western blot, RIP | LncRNA 6030408B16RIK competitively bound to miR-326-3p and then elevated WISP2 expression. | 32255479 | ||||
Display: |
|